A groundbreaking review highlights significant advancements in the understanding and treatment of cerebral vascular ...

AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program.

Phase 1b clinical data underpins sozinibercept’s potential as a novel, first-in-class VEGF-C/D ‘trap’ to improve visual and anatomic outcomes in ...

The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in advanced ...

The following is a summary of “Clinical response and corresponding blood transcriptome pathways before and after treatment of ...

Aberrant activation of the Ras/Raf/MAPK/ERK kinase/extracellular signal-regulated kinase cascade and the VEGF pathway are commonly observed in breast cancer cells leading to malignant cell ...

REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea ...

Its lead candidate, ivonescimab (SMT112), a bispecific antibody targeting PD-1 and VEGF pathways, is in late-stage trials for metastatic non-small-cell lung cancer (NSCLC) and shows promising ...

Sequential therapy with either continued VEGF receptor inhibition (tyrosine kinase inhibitor [TKI]-TKI sequence) or alternate pathway inhibition (TKI–mTOR sequence) results in prolonged disease ...

“The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in ...

PM-8002 is under clinical development by Biotheus and currently in Phase II for Small-Cell Lung Cancer. According to GlobalData, Phase II drugs for Small-Cell Lung Cancer have a 26% phase transition ...

Metastatic clear cell renal cell carcinoma (mccRCC), an aggressive type of kidney cancer, has historically presented limited treatment options. Immune checkpoint inhibitors, a form of immunotherapy, ...